

Cabometyx® (cabozantinib) - New indication

- On January 14, 2019, <u>Exelixis announced</u> the FDA approval of <u>Cabometyx (cabozantinib)</u> tablets, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with <u>Nexavar</u>[®] (sorafenib).
 - Cabometyx is also approved for the treatment of patients with advanced renal cell carcinoma.
- HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in the U.S.
- The approval of Cabometyx's new indication was based on CELESTIAL, a study in in patients with HCC who had previously received Nexavar and had Child Pugh Class A liver impairment. Patients were randomized to receive Cabometyx or placebo until disease progression or unacceptable toxicity. The primary efficacy outcome measure was overall survival (OS). Additional outcome measures were progression-free survival (PFS) and objective response rate (ORR).
 - Median OS was 10.2 months (95% CI: 9.1, 12.0) with Cabometyx vs. 8.0 months (95% CI: 6.8, 9.4) with placebo (HR 0.76, 95% CI: 0.63, 0.92; p = 0.0049).
 - Median PFS was 5.2 months (95% CI: 4.0, 5.5) with cabozantinib vs. 1.9 months (95% CI: 1.9, 1.9) with placebo (HR 0.44, 95% CI: 0.36, 0.52; p < 0.0001).
 - ORR was 4% (95% CI: 2.3, 6.0) with cabozantinib vs. 0.4% (95% CI: 0.0, 2.3) with placebo (p = 0.0086).
- In addition to the new indication, the *Warnings and Precautions* section of the labeling was updated to include proteinuria, osteonecrosis of the jaw, and wound complications.
- The recommended dosage of Cabometyx for both indications is 60 mg orally once daily without food until disease progression or unacceptable toxicity.
 - Cabometyx should be administered at least 1 hour before or at least 2 hours after eating.
 - Cabometyx tablets should not be substituted with Cometriq® (cabozantinib) capsules.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.